Who are Tucidinostat, Azacitidine combined with CHOP's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tucidinostat-azacitidine-combined-with-chop.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Tucidinostat, Azacitidine combined with CHOP — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tucidinostat, Azacitidine combined with CHOP (Tucidinostat, Azacitidine combined with CHOP) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histone deacetylase inhibitor and hypomethylating agent, chemotherapy regimen. Area: Oncology.

phase 3 Histone deacetylase inhibitor and hypomethylating agent, chemotherapy regimen Histone deacetylases, DNA methyltransferases Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Tucidinostat, Azacitidine combined with CHOP (Tucidinostat, Azacitidine combined with CHOP) — Peking Union Medical College Hospital. Tucidinostat is a histone deacetylase inhibitor, while Azacitidine is a hypomethylating agent, and CHOP is a chemotherapy regimen.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tucidinostat, Azacitidine combined with CHOP TARGET	Tucidinostat, Azacitidine combined with CHOP	Peking Union Medical College Hospital	phase 3	Histone deacetylase inhibitor and hypomethylating agent, chemotherapy regimen	Histone deacetylases, DNA methyltransferases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histone deacetylase inhibitor and hypomethylating agent, chemotherapy regimen class)

Peking Union Medical College Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tucidinostat, Azacitidine combined with CHOP — Competitive Intelligence Brief. https://druglandscape.com/ci/tucidinostat-azacitidine-combined-with-chop. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab